SK55699A3 - Use of 17-difluoromethylene estratrienes for the preparation of a medicament for lowering plasma levels of lp(a) and inhibiting the generation of apo(a) and a pharmaceutical composition - Google Patents

Use of 17-difluoromethylene estratrienes for the preparation of a medicament for lowering plasma levels of lp(a) and inhibiting the generation of apo(a) and a pharmaceutical composition Download PDF

Info

Publication number: SK55699A3
Authority: SK; Slovakia
Prior art keywords: hydrogen; compound; formula; disease; apo
Prior art date: 1996-10-30

Application number

SK556-99A

Other languages

English (en)

Slovak (sk)

Inventor

Katalin Kauser

Gabor Rubanyi

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-30

Filing date

1997-10-18

Publication date

2000-08-14

1997-10-18 Application filed by Schering Ag filed Critical Schering Ag

2000-08-14 Publication of SK55699A3 publication Critical patent/SK55699A3/sk

Links

102100040214 Apolipoprotein(a) Human genes 0.000 title claims abstract description 48
101710115418 Apolipoprotein(a) Proteins 0.000 title claims abstract description 45
230000036470 plasma concentration Effects 0.000 title claims abstract description 30
230000002401 inhibitory effect Effects 0.000 title claims abstract description 15
239000008194 pharmaceutical composition Substances 0.000 title claims description 16
238000002360 preparation method Methods 0.000 title claims description 15
239000003814 drug Substances 0.000 title claims description 6
150000001875 compounds Chemical class 0.000 claims abstract description 89
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 72
239000001257 hydrogen Substances 0.000 claims abstract description 72
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 48
150000002431 hydrogen Chemical class 0.000 claims abstract description 24
125000000217 alkyl group Chemical group 0.000 claims abstract description 21
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 13
125000003545 alkoxy group Chemical group 0.000 claims abstract description 10
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 10
125000001424 substituent group Chemical group 0.000 claims abstract description 9
201000010099 disease Diseases 0.000 claims description 29
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
230000015572 biosynthetic process Effects 0.000 claims description 16
239000000203 mixture Substances 0.000 claims description 15
230000002028 premature Effects 0.000 claims description 11
IODAWLSYSGQMSN-WWNBULGVSA-N (8s,9s,13s,14s)-17-(difluoromethylidene)-13-ethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-ol Chemical compound OC1=CC=C2[C@H]3CC[C@](CC)(C(CC4)=C(F)F)[C@@H]4[C@@H]3CCC2=C1 IODAWLSYSGQMSN-WWNBULGVSA-N 0.000 claims description 10
208000029078 coronary artery disease Diseases 0.000 claims description 10
-1 17-difluoromethylene-18-methylestra-1,3,5 (10) -trien-3-ol compound Chemical class 0.000 claims description 8
200000000007 Arterial disease Diseases 0.000 claims description 8
241000699670 Mus sp. Species 0.000 claims description 8
206010012601 diabetes mellitus Diseases 0.000 claims description 6
201000001320 Atherosclerosis Diseases 0.000 claims description 5
208000006011 Stroke Diseases 0.000 claims description 5
230000009467 reduction Effects 0.000 claims description 4
206010008118 cerebral infarction Diseases 0.000 claims description 3
208000026106 cerebrovascular disease Diseases 0.000 claims description 3
238000000034 method Methods 0.000 abstract description 23
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
150000003839 salts Chemical class 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
108010007622 LDL Lipoproteins Proteins 0.000 description 9
102000007330 LDL Lipoproteins Human genes 0.000 description 9
239000004615 ingredient Substances 0.000 description 8
239000000546 pharmaceutical excipient Substances 0.000 description 8
238000009472 formulation Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
235000019359 magnesium stearate Nutrition 0.000 description 6
210000004291 uterus Anatomy 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
241000699660 Mus musculus Species 0.000 description 5
239000008101 lactose Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000011830 transgenic mouse model Methods 0.000 description 5
102000013566 Plasminogen Human genes 0.000 description 4
108010051456 Plasminogen Proteins 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 4
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 4
230000037396 body weight Effects 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
229940068918 polyethylene glycol 400 Drugs 0.000 description 4
229960004063 propylene glycol Drugs 0.000 description 4
150000003254 radicals Chemical class 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
229960000187 tissue plasminogen activator Drugs 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101000889990 Homo sapiens Apolipoprotein(a) Proteins 0.000 description 3
108010033266 Lipoprotein(a) Proteins 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
208000005764 Peripheral Arterial Disease Diseases 0.000 description 3
208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
239000000262 estrogen Substances 0.000 description 3
229940011871 estrogen Drugs 0.000 description 3
239000003527 fibrinolytic agent Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
230000003902 lesion Effects 0.000 description 3
229940012957 plasmin Drugs 0.000 description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000000186 progesterone Substances 0.000 description 3
229960003387 progesterone Drugs 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
208000019553 vascular disease Diseases 0.000 description 3
BSGPCYMUVXVZHZ-DCTDBFQOSA-N (9r,10s,13s)-17-(difluoromethylidene)-13-methyl-2,3,4,5,9,10,11,12-octahydro-1h-cyclopenta[a]phenanthrene Chemical class C([C@@H]1[C@H]2CC3)CCCC1C=CC2=C1[C@@]3(C)C(=C(F)F)C=C1 BSGPCYMUVXVZHZ-DCTDBFQOSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
240000001851 Artemisia dracunculus Species 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
208000031481 Pathologic Constriction Diseases 0.000 description 2
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000002965 anti-thrombogenic effect Effects 0.000 description 2
239000000010 aprotic solvent Substances 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
229920003086 cellulose ether Polymers 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
230000006870 function Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000007788 liquid Substances 0.000 description 2
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000009245 menopause Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
208000031225 myocardial ischemia Diseases 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000007787 solid Substances 0.000 description 2
208000037804 stenosis Diseases 0.000 description 2
230000036262 stenosis Effects 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
229960003604 testosterone Drugs 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
VVFGLBKYBBUTRO-UHFFFAOYSA-N 1-[difluoromethyl(ethoxy)phosphoryl]oxyethane Chemical compound CCOP(=O)(C(F)F)OCC VVFGLBKYBBUTRO-UHFFFAOYSA-N 0.000 description 1
OXEDXHIBHVMDST-UHFFFAOYSA-N 12Z-octadecenoic acid Natural products CCCCCC=CCCCCCCCCCCC(O)=O OXEDXHIBHVMDST-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
208000031104 Arterial Occlusive disease Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
241000289669 Erinaceus europaeus Species 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
206010033307 Overweight Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
241000288906 Primates Species 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
BWWJPRJTQKEZQL-UHFFFAOYSA-N [difluoromethyl(phenyl)phosphoryl]benzene Chemical compound C=1C=CC=CC=1P(=O)(C(F)F)C1=CC=CC=C1 BWWJPRJTQKEZQL-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000003263 anabolic agent Substances 0.000 description 1
229940070021 anabolic steroids Drugs 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
230000001567 anti-fibrinolytic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
208000021328 arterial occlusion Diseases 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
OCFSGVNHPVWWKD-UHFFFAOYSA-N butylaluminum Chemical compound [Al].[CH2]CCC OCFSGVNHPVWWKD-UHFFFAOYSA-N 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
230000003822 cell turnover Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000013367 dietary fats Nutrition 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
125000002228 disulfide group Chemical group 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
208000028208 end stage renal disease Diseases 0.000 description 1
201000000523 end stage renal failure Diseases 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
238000006266 etherification reaction Methods 0.000 description 1
235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
230000029142 excretion Effects 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
235000009200 high fat diet Nutrition 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
208000023589 ischemic disease Diseases 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229920003087 methylethyl cellulose Polymers 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
238000009806 oophorectomy Methods 0.000 description 1
238000011474 orchiectomy Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
239000000473 propyl gallate Substances 0.000 description 1
235000010388 propyl gallate Nutrition 0.000 description 1
229940075579 propyl gallate Drugs 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
230000007017 scission Effects 0.000 description 1
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
230000002966 stenotic effect Effects 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940117013 triethanolamine oleate Drugs 0.000 description 1
230000007306 turnover Effects 0.000 description 1
230000001836 utereotrophic effect Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SK556-99A 1996-10-30 1997-10-18 Use of 17-difluoromethylene estratrienes for the preparation of a medicament for lowering plasma levels of lp(a) and inhibiting the generation of apo(a) and a pharmaceutical composition SK55699A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/739,840 US5773432A (en)	1996-10-30	1996-10-30	Method for lowering plasma levels of lipoprotein(a)
PCT/EP1997/005774 WO1998018429A2 (fr)	1996-10-30	1997-10-18	Procede pour abaisser les taux plasmatiques de lipoproteines (a)

Publications (1)

Publication Number	Publication Date
SK55699A3 true SK55699A3 (en)	2000-08-14

Family

ID=24973992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK556-99A SK55699A3 (en)	1996-10-30	1997-10-18	Use of 17-difluoromethylene estratrienes for the preparation of a medicament for lowering plasma levels of lp(a) and inhibiting the generation of apo(a) and a pharmaceutical composition

Country Status (16)

Country	Link
US (1)	US5773432A (fr)
EP (1)	EP0941096A2 (fr)
JP (1)	JP2001508040A (fr)
CN (1)	CN1235548A (fr)
AU (1)	AU4948497A (fr)
BR (1)	BR9712580A (fr)
CA (1)	CA2269670A1 (fr)
CZ (1)	CZ150099A3 (fr)
HU (1)	HUP9904498A3 (fr)
IL (1)	IL129220A0 (fr)
IS (1)	IS5022A (fr)
NO (1)	NO992061L (fr)
PL (1)	PL332956A1 (fr)
SK (1)	SK55699A3 (fr)
TR (1)	TR199900922T2 (fr)
WO (1)	WO1998018429A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19509729A1 (de) *	1995-03-13	1996-09-19	Schering Ag	17-Difluormethylen-Estratriene
EP1074634B1 (fr) *	1999-07-09	2002-10-02	Institut Pasteur De Lille	Procédé pour le diagnostic ou le prognostic de la maladie d'Alzheimer: Composition therapeutique pour la prévention ou le traitement de la maladie d'Alzheimer
US6998501B1 (en)	1999-08-30	2006-02-14	Ocean Nutrition Canada Limited	Nutritional supplement for lowering serum triglyceride and cholesterol levels
US6495534B2 (en) *	2000-05-15	2002-12-17	Pharmacia & Upjohn Spa	Stabilized aqueous suspensions for parenteral use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4133814A (en) *	1975-10-28	1979-01-09	Eli Lilly And Company	2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) *	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes
DE3741800A1 (de) *	1987-12-07	1989-06-15	Schering Ag	17-halogenmethylen-estratriene
TW383306B (en) *	1992-12-22	2000-03-01	Lilly Co Eli	New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5496828A (en) *	1994-08-22	1996-03-05	Eli Lilly And Company	Methods of inhibiting ulcerative mucositis
US5484808A (en) *	1995-02-09	1996-01-16	Eli Lilly And Company	Methods of inhibiting cell-cell adhesion
US5489611A (en) *	1995-02-10	1996-02-06	Warner-Lambert Company	Method for lowering plasma levels of lipoprotein (a)
DE19509729A1 (de) *	1995-03-13	1996-09-19	Schering Ag	17-Difluormethylen-Estratriene

1996
- 1996-10-30 US US08/739,840 patent/US5773432A/en not_active Expired - Fee Related
1997
- 1997-10-18 AU AU49484/97A patent/AU4948497A/en not_active Abandoned
- 1997-10-18 SK SK556-99A patent/SK55699A3/sk unknown
- 1997-10-18 PL PL97332956A patent/PL332956A1/xx unknown
- 1997-10-18 IL IL12922097A patent/IL129220A0/xx unknown
- 1997-10-18 CA CA002269670A patent/CA2269670A1/fr not_active Abandoned
- 1997-10-18 HU HU9904498A patent/HUP9904498A3/hu unknown
- 1997-10-18 CN CN97199249A patent/CN1235548A/zh active Pending
- 1997-10-18 EP EP97912202A patent/EP0941096A2/fr not_active Withdrawn
- 1997-10-18 TR TR1999/00922T patent/TR199900922T2/xx unknown
- 1997-10-18 CZ CZ991500A patent/CZ150099A3/cs unknown
- 1997-10-18 WO PCT/EP1997/005774 patent/WO1998018429A2/fr not_active Ceased
- 1997-10-18 BR BR9712580-6A patent/BR9712580A/pt not_active Application Discontinuation
- 1997-10-18 JP JP51999698A patent/JP2001508040A/ja active Pending
1999
- 1999-04-09 IS IS5022A patent/IS5022A/is unknown
- 1999-04-29 NO NO992061A patent/NO992061L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
TR199900922T2 (xx)	1999-07-21
PL332956A1 (en)	1999-10-25
NO992061D0 (no)	1999-04-29
CZ150099A3 (cs)	1999-11-17
IL129220A0 (en)	2000-02-17
BR9712580A (pt)	1999-12-07
EP0941096A2 (fr)	1999-09-15
WO1998018429A2 (fr)	1998-05-07
HUP9904498A3 (en)	2000-06-28
AU4948497A (en)	1998-05-22
HUP9904498A2 (hu)	2000-05-28
WO1998018429A3 (fr)	1998-10-08
CN1235548A (zh)	1999-11-17
US5773432A (en)	1998-06-30
JP2001508040A (ja)	2001-06-19
NO992061L (no)	1999-04-29
CA2269670A1 (fr)	1998-05-07
IS5022A (is)	1999-04-09

Publication	Publication Date	Title
JP2888453B2 (ja)	1999-05-10	ニューモシスティス−カリニ肺炎の治療用または予防用の製薬組成物
EP0038674A1 (fr)	1981-10-28	Compositions médicinales pour le traitement des maladies allergiques
ZA200100743B (en)	2002-05-08	Use of biogenic estrogen sulfamates for hormone replacement therapy.
CN1200126A (zh)	1998-11-25	1,3,5(10)－雌三烯的氨基磺酸酯衍生物、其制备方法和含有这些化合物的药物
WO1995030412A1 (fr)	1995-11-16	Potentialisateur de cytokine et remede pour des maladies dans lesquelles l'activite de la cytokine est reduite
SK55699A3 (en)	2000-08-14	Use of 17-difluoromethylene estratrienes for the preparation of a medicament for lowering plasma levels of lp(a) and inhibiting the generation of apo(a) and a pharmaceutical composition
JPH03294230A (ja)	1991-12-25	子宮内膜症治療剤
AU720013B2 (en)	2000-05-18	Use of raloxifene and of related compounds for the manufacture of a medicament for lowering plasma levels of lipoprotein(A)
JP2021534208A (ja)	2021-12-09	高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法
WO2003103683A1 (fr)	2003-12-18	Utilisation d'estetrol et de ses analogues pour le traitement ou la prevention de pathologies cardio-vasculaires, notamment de l'atherosclerose
US20020028793A1 (en)	2002-03-07	Use of estrogens and delta-gonadien-21-3,20-diones
CN104220083A (zh)	2014-12-17	用于治疗动脉硬化性血管疾病的方法和组合物
EP1769793A1 (fr)	2007-04-04	Médicament thérapeutique ou préventif pour le diabète, l'obésité ou l'artériosclérose
MXPA99003614A (en)	2000-09-04	A method for lowering plasma levels of lipoprotein(a)
JPH09169650A (ja)	1997-06-30	遊離ラジカルの誘発する疾患状態を治療または阻害するための医薬組成物
HK1023060A (en)	2000-09-01	A method for lowering plasma levels of lipoprotein(a)
AU2002305164B2 (en)	2005-07-28	Method of inhibiting adhesion formation
JPH03236324A (ja)	1991-10-22	血管新生阻害剤
KR20050092568A (ko)	2005-09-22	간섬유화 및 간경화 치료 효과를 갖는 아시아트산 유도체
EP4522153A1 (fr)	2025-03-19	Procédés de traitement utilisant un inhibiteur de kinase 1a à double spécificité régulée par la phosphorylation de la tyrosine (dyrk1a)
JPH0769883A (ja)	1995-03-14	アロマターゼ阻害剤
AU2002305164A1 (en)	2003-04-17	Method of inhibiting adhesion formation
CA2652483A1 (fr)	2007-11-22	Utilisation de la drospirenone pour la prevention de l'hypertension arterielle chez les patients pre-hypertendus
MXPA99002272A (en)	2000-12-06	Compositions and methods for the treatment of atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoi
WO2003055488A1 (fr)	2003-07-10	Remedes ou traitements preventifs contre des maladies associees a la fibrose tissulaire